Popular posts
- Rosetta Genomics - Mining Gold Out of Junk (Part I)
- Immunogen and Seattle Genetics – On The Verge Of An Inflection Point
- Will Synta Break A 30 Year Old Record? (Part I)
- Investing in microRNA - Beware of Hype, Follow The Money
- About
- Genentech’s Shiny New Platform
- Immunogen’s lead candidate - Herceptin-DM1 (T-DM1)
- Seattle Genetics’ SGN-40 – The big comeback
- Micromet - Biting Cancer (Part II)
- Rosetta Genomics - Mining Gold Out of Junk (Part II)
Powered by FireStats-
Recent Comments
Tags
ADC ALNY AMGN AML auristatin AVE1642 AVE9633 AZN cd19 cd30 CD33 CEGE CNXT cr011-vc-MMAE CRGN DNA DNDN EphA2 GENZ IFX IKAN IMCL IMGN IMGN901 ISIS MEDX melanoma MITI Mylotarg NHL ORCT PARD Rituxan ROSG SGEN SGN-30 SGN-33 SGN-35 SGN-40 SNTA SNY VDSL VION WYE-
Meta
Blogroll
META
RECENT POSTS
CATEGORIES
- bispecific antibodies (4)
- cancer vaccine (7)
- chemotherapy (2)
- diagnostics (2)
- miRNA (3)
- Monocloncal antibodies (32)
- solid tumors (9)
- technology (5)
- Uncategorized (15)
Wordpress theme by Abhishek Tripathi of Mediawick Digital Solutions